214 related articles for article (PubMed ID: 25534446)
1. Prospective iterative trial of proteasome inhibitor-based desensitization.
Woodle ES; Shields AR; Ejaz NS; Sadaka B; Girnita A; Walsh RC; Alloway RR; Brailey P; Cardi MA; Abu Jawdeh BG; Roy-Chaudhury P; Govil A; Mogilishetty G
Am J Transplant; 2015 Jan; 15(1):101-18. PubMed ID: 25534446
[TBL] [Abstract][Full Text] [Related]
2. Bortezomib-based antibody reduction therapy: the first step to “true” desensitization?
Budde K; Lehner LJ
Am J Transplant; 2015 Jan; 15(1):10-12. PubMed ID: 25534967
[No Abstract] [Full Text] [Related]
3. HLA desensitization with bortezomib in a highly sensitized pediatric patient.
May LJ; Yeh J; Maeda K; Tyan DB; Chen S; Kaufman BD; Bernstein D; Rosenthal DN; Hollander SA
Pediatr Transplant; 2014 Dec; 18(8):E280-2. PubMed ID: 25174602
[TBL] [Abstract][Full Text] [Related]
4. Comparison between bortezomib and rituximab in the treatment of antibody-mediated renal allograft rejection.
Waiser J; Budde K; Schütz M; Liefeldt L; Rudolph B; Schönemann C; Neumayer HH; Lachmann N
Nephrol Dial Transplant; 2012 Mar; 27(3):1246-51. PubMed ID: 21852274
[TBL] [Abstract][Full Text] [Related]
5. Differential modulation of donor-specific antibodies after B-cell depleting therapies to cure chronic antibody mediated rejection.
Touzot M; Couvrat-Desvergnes G; Castagnet S; Cesbron A; Renaudin K; Cantarovich D; Giral M
Transplantation; 2015 Jan; 99(1):63-8. PubMed ID: 25029384
[TBL] [Abstract][Full Text] [Related]
6. Treatment of Biopsy-Proven Acute Antibody-Mediated Rejection Using Thymoglobulin (ATG) Monotherapy and a Combination of Rituximab, Intravenous Immunoglobulin, and Plasmapheresis: Lesson Learned from Primary Experience.
Zheng J; Xue W; Qing X; Jing X; Hou J; Tian X; Guo Q; He X; Cai J
Clin Transpl; 2014; ():223-30. PubMed ID: 26281149
[TBL] [Abstract][Full Text] [Related]
7. Outcome of Desensitization Therapy in Immunologically High-Risk Kidney Transplantation: Single-Center Experience.
Sinangil A; Ucar ZA; Koc Y; Barlas S; Abouzahir S; Ecder ST; Akin EB
Transplant Proc; 2019 Sep; 51(7):2268-2273. PubMed ID: 31358450
[TBL] [Abstract][Full Text] [Related]
8. Bortezomib as an adjuvant to conventional therapy in the treatment of antibody mediated rejection (AMR): the full spectrum.
Al Meshari K; Pall A; Elgamal H; Alzayer F; Altalhi M
Clin Transpl; 2010; ():383-90. PubMed ID: 21696055
[TBL] [Abstract][Full Text] [Related]
9. Durability of antibody removal following proteasome inhibitor-based therapy.
Everly MJ; Terasaki PI; Trivedi HL
Transplantation; 2012 Mar; 93(6):572-7. PubMed ID: 22262128
[TBL] [Abstract][Full Text] [Related]
10. Highly Sensitized Patients: Miami Transplant Institute Experience.
Mattiazzi AD; Centeno A; Amador A; Fernandez-Bango C; Scowby CD; O'Rourke M; Hill-Matthie T; Patel R; Barrios F; Ruiz P; Chen L; Saghesima J; Ciancio G; Burke GW; Goldstein M; Chandar J; Contreras G; Roth D; Kupin W; Guerra G; Vianna R
Clin Transpl; 2014; ():171-8. PubMed ID: 26281142
[TBL] [Abstract][Full Text] [Related]
11. Reduction of alloantibodies via proteasome inhibition in cardiac transplantation.
Patel J; Everly M; Chang D; Kittleson M; Reed E; Kobashigawa J
J Heart Lung Transplant; 2011 Dec; 30(12):1320-6. PubMed ID: 21968130
[TBL] [Abstract][Full Text] [Related]
12. Four-year allograft survival in a highly sensitized combined liver-kidney transplant patient despite unsuccessful anti-HLA antibody reduction with rituximab, splenectomy, and bortezomib.
Koch M; Gräser C; Lehnhardt A; Pollok JM; Kröger N; Verboom M; Thaiss F; Eiermann T; Nashan B
Transpl Int; 2013 Aug; 26(8):e64-8. PubMed ID: 23672514
[TBL] [Abstract][Full Text] [Related]
13. Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation.
Vo AA; Peng A; Toyoda M; Kahwaji J; Cao K; Lai CH; Reinsmoen NL; Villicana R; Jordan SC
Transplantation; 2010 May; 89(9):1095-102. PubMed ID: 20110854
[TBL] [Abstract][Full Text] [Related]
14. Rapid reduction in donor-specific anti-human leukocyte antigen antibodies and reversal of antibody-mediated rejection with bortezomib in pediatric heart transplant patients.
Morrow WR; Frazier EA; Mahle WT; Harville TO; Pye SE; Knecht KR; Howard EL; Smith RN; Saylors RL; Garcia X; Jaquiss RD; Woodle ES
Transplantation; 2012 Feb; 93(3):319-24. PubMed ID: 22179403
[TBL] [Abstract][Full Text] [Related]
15. Desensitization across the HLA barrier in kidney transplantaion.
Mohamed MA; Lorentzen D; Kim J; Djamali A
Front Biosci (Schol Ed); 2011 Jun; 3(3):929-36. PubMed ID: 21622242
[TBL] [Abstract][Full Text] [Related]
16. Abrogation of anti-HLA antibodies via proteasome inhibition.
Trivedi HL; Terasaki PI; Feroz A; Everly MJ; Vanikar AV; Shankar V; Trivedi VB; Kaneku H; Idica AK; Modi PR; Khemchandani SI; Dave SD
Transplantation; 2009 May; 87(10):1555-61. PubMed ID: 19461494
[TBL] [Abstract][Full Text] [Related]
17. A prospective, iterative, adaptive trial of carfilzomib-based desensitization.
Tremblay S; Driscoll JJ; Rike-Shields A; Hildeman DA; Alloway RR; Girnita AL; Brailey PA; Woodle ES
Am J Transplant; 2020 Feb; 20(2):411-421. PubMed ID: 31550069
[TBL] [Abstract][Full Text] [Related]
18. Lung transplantation across donor-specific anti-human leukocyte antigen antibodies: utility of bortezomib therapy in early graft dysfunction.
Stuckey LJ; Kamoun M; Chan KM
Ann Pharmacother; 2012 Jan; 46(1):e2. PubMed ID: 22202499
[TBL] [Abstract][Full Text] [Related]
19. Prognostic tools to assess candidacy for and efficacy of antibody-removal therapy.
Pinelli DF; Zachary AA; Friedewald JJ; Gjertson DW; Evans MA; Chatroop EN; Leffell MS; Vo AA; Jordan SC; Montgomery RA; Tambur AR
Am J Transplant; 2019 Feb; 19(2):381-390. PubMed ID: 29981209
[TBL] [Abstract][Full Text] [Related]
20. One-Year Outcomes of Living Related Kidney Transplant in Patients With Preformed HLA Donor-Specific Antibodies: A Single-Center Experience in Malaysia.
Jalalonmuhali M; Ng KP; Mohd Shariff NH; Lee YW; Wong AH; Gan CC; Lim SK
Transplant Proc; 2020; 52(6):1718-1722. PubMed ID: 32448671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
